Novel test proves its worth for detecting white spot syndrome virus

Australian biotech company Genics has exceeded global standards in pathogen testing for white spot syndrome virus (WSSV) – a pathogen that can wreak havoc in commercial shrimp farms.

Giant tiger prawn infected with white spot syndrome virus 

White spot syndrome virus moves quickly, killing up to 100 percent of affected farmed shrimp © Genics

White spot syndrome virus (WSSV) is one of the most feared infectious diseases in the shrimp industry, inflicting estimated production losses world-wide of up to $1 billion annually. But new research has shown that Shrimp MultiPath – technology used to identify pathogens like WSSV, which was invented by Queensland-based biotechnology company Genics – has been proven to exceed the standards for efficiency and sensitivity in commercial shrimp virus testing.

Dr Melony Sellars, CEO of Genics, said in a press release: “Not only are we benchmarking against world standard testing real-time PCR assays, but then also exceeding these parameters, meaning we are supplying our industry with higher efficiency and value for money with this cutting-edge technology against white spot and the 12 other pathogens of commercial importance in the platform.”

She continued: “Ultimately, with widespread use of these tests in early pathogen detection, we can support those farmers working to improve food security.”

Dr Melony Sellars, CEO of Genics and inventor of Shrimp MultiPath, in the Genics lab in Queensland © Genics

Shrimp are well known for their high volumes of protein, amino acids and healthy fats – making them an important part of global food supply. Unfortunately, these invertebrates can also contract numbers of deadly pathogens, causing millions of dollars of food and stock waste. Effective surveillance testing and targeted diagnosis as part of cohesive biosecurity measures are all ways that shrimp industries and authorities can receive early alerts about the potential threat of WSSV in populations.

Shrimp MultiPath is a multiplexed assay panel and has routinely been used since 2018 for commercial shrimp aquaculture sample testing. It is used to test for infection in apparently healthy animals for early detection and early risk mitigation, translocation testing, confirmation of clinical disease, and in conjunction with advanced breeding strategies.

The performance of Shrimp MultiPath was tested by an independent laboratory – against DNA and RNA clinical samples, the World Organisation for Animal Health (WOAH-OIE) recommended real-time PCR assay, and the newly adapted CSIRO, Australia’s national science agency, real-time PCR assay – in an empirical assessment for this latest peer reviewed research study. It was assessed for repeatability, sensitivity, and specificity on Bayesian latent class models, using whiteleg shrimp (Litopenaeus vannamei) tissue samples.

By The Fish Site

Reference: https://thefishsite.com/articles/novel-test-proves-its-worth-for-detecting-white-spot-syndrome-virus

DOMESTICATED SHRIMP POSTLARVAE – THE KEY TO SUCCESS

See more:

• AI Chatbots and Aquaculture Professionalism
• Is EHP now the key health concern for Asian shrimp producers?
• ASC opens certification to Feed Standard